pochi: pembrolizumab, capox and bevacizumab in pmmr/mss crc at esmo 2024
Published 2 days ago • 10 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:16
pochi: pembrolizumab, capox and bevacizumab in pmmr/mss colorectal cancer
-
2:53
pembrolizumab, bevacizumab & capox for pmmr/mss mcrc in the pochi trial
-
1:12
crc highlights from esmo wcgic 2021
-
1:03
keynote-811: final os results of pembrolizumab, trastuzumab and chemotherapy in g/gej
-
0:54
perioperative pembrolizumab for stomach cancer treatment
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
16:11
esmo 2024 - daejin abidoye
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
22:18
esmo 2024
-
51:30
bladder cancer innovations: esmo 2024 highlights w/ dr. andrea apollo | backtable urology ep. 193
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
0:21
medias klinikum - animation regional chemotherapy and chemofiltration for pelvic tumors
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
0:50
advancements in immunotherapy for metastatic colorectal cancer
-
1:25
phase ii study of neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with mibc
-
2:59
promise-meso: pembrolizumab vs. standard chemotherapy for mesothelioma
-
2:21
phase i study of ipatasertib with chemotherapy and atezolizumab